A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia

Blood

Volumn 126, Issue 25, 2015, Pages 2686-2694

  O'Brien, Susan M ^a   Lamanna, Nicole ^b   Kipps, Thomas J ^c   Flinn, Ian ^d   Zelenetz, Andrew D ^e   Burger, Jan A ^f   Keating, Michael ^f   Mitra, Siddhartha ^g   Holes, Leanne ^h   Yu, Albert S ^h   Johnson, David M ^h   Miller, Langdon L ^h   Kim, Yeonhee ^h   Dansey, Roger D ^h   Dubowy, Ronald L ^h   Coutre, Steven E ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d SARAH CANNON RESEARCH INSTITUTE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANALGESIC AGENT; ANTIHISTAMINIC AGENT; ASPARTATE AMINOTRANSFERASE; GLUCOCORTICOID; IDELALISIB; PROTEIN P53; RITUXIMAB; STEROID; VALACICLOVIR; ANTINEOPLASTIC AGENT; PURINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; CANCER PATIENT; CELLULITIS; CHILL; CHRONIC LYMPHATIC LEUKEMIA; COLITIS; CONSTIPATION; COUGHING; CYTOMEGALOVIRUS INFECTION; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GENE MUTATION; GERIATRIC PATIENT; HEART INFARCTION; HUMAN; HYPOXIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NIGHT SWEAT; OPPORTUNISTIC INFECTION; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RESPIRATORY FAILURE; SIDE EFFECT; URINARY TRACT INFECTION; VOMITING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MORTALITY; MULTICENTER STUDY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; PURINES; QUINAZOLINONES; RITUXIMAB; TREATMENT OUTCOME;

EID: 84951268355     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-03-630947     Document Type: Article

References (36)

1. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet. 2008;371(9617):1017-1029.
2. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252-271.
3. Eichhorst B, Goede V, Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50(2):171-178.
4. Redaelli A, Laskin BL, Stephens JM, Botteman MF, Pashos CL. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care (Engl). 2004;13(3):279-287.
5. Keating MJ, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma. 2002; 43(9):1755-1762.
6. Zelenetz AD, Gordon LI, Wierda WG, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines-): Non-Hodgkin lymphomas, v.2. 2015. http://www.nccn.org/professionals/physician-gls/pdf/nhl.pdf. Accessed May 2, 2015.
7. Goede V, Hallek M. Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: Considerations in the elderly. Drugs Aging. 2011; 28(3):163-176.
8. Tadmor T, Polliack A. Optimal management of older patients with chronic lymphocytic leukemia: Some facts and principles guiding therapeutic choices. Blood Rev. 2012;26(1):15-23.
9. Badoux XC, Keating MJ, Wen S, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011; 118(13):3489-3498.
10. Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 2013;34(12):592-601.
11. Herman SE, Johnson AJ. Molecular pathways: Targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia. Clin Cancer Res. 2012;18(15):4013-4018.
12. Cuní S, Pérez-Aciego P, Pérez-Chacón G, et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia. 2004;18(8): 1391-1400.
13. Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 39-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118(13):3603-3612.
14. Davids MS, Brown JR. Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53(12): 2362-2370.
15. Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. 2003;3(4):317-330.
16. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006; 7(8):606-619.
17. Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-d inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116(12):2078-2088.
18. Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011; 117(2):591-594.
19. Furman RR, deVos S, Barrientos JC, et al. Longterm follow-up of a phase 1 study of idelalisib (ZYDELIG-) in combination with anti-CD20 antibodies (rituximab [R] or ofatumumab [O]) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) [abstract]. Blood. 2014;124(21). Abstract 5653.
20. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110d, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123(22):3390-3397.
21. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370(11):997-1007.
22. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19(8): 2165-2170.
23. Hainsworth JD, Litchy S, Barton JH, et al; Minnie Pearl Cancer Research Network. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003;21(9):1746-1751.
24. Hallek M, Cheson BD, Catovsky D, et al; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
25. Webb HK, Chen H, Yu AS, et al. Clinical pharmacokinetics of CAL 101, a p110d isoformselective PI3K inhibitor, following single- and multiple-dose administration in healthy volunteers and patients with hematological malignancies [abstract]. Blood. 2010;116:(21). Abstract 1774.
26. Piro LD, White CA, Grillo-López AJ, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1999;10(6):655-661.
27. Houldsworth J, Guttapalli A, Thodima V, et al. Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2014;55(4):920-928.
28. Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2008; 49(1):49-56.
29. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101-1110.
30. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29): 4473-4479.
31. Gonzalez D, Martinez P, Wade R, et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: Results from the LRF CLL4 trial. J Clin Oncol. 2011;29(16): 2223-2229.
32. Coutre SE, Furman RR, Sharman JP, et al. Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL. J Clin Oncol. 2014;32(suppl 5). Abstract: 7012.
33. Patton DT, Garden OA, Pearce WP, et al. Cutting edge: The phosphoinositide 3-kinase p110 delta is critical for the function of CD41CD251Foxp31 regulatory T cells. J Immunol. 2006;177(10): 6598-6602.
34. Okkenhaug K, Bilancio A, Farjot G, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science. 2002;297(5583):1031-1034.
35. Uno JK, Rao KN, Matsuoka K, et al. Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110d. Gastroenterology. 2010;139(5): 1642-1653, 1653.e1-1653.e6.
36. Molnarfi N, Brandt KJ, Gruaz L, Dayer JM, Burger D. Differential regulation of cytokine production by PI3Kdelta in human monocytes upon acute and chronic inflammatory conditions. Mol Immunol. 2008;45(12):3419-3427.